4
Changes in Ownership
Roivant Sciences Ltd. Filed Acc 0001635088-26-000017
President & Immunovant CEO sold 200,000 shares at $26.49 ($5,298,000)
- President & Immunovant CEO acquired 200,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Venker Eric · President & Immunovant CEO
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-13 | Exercise or conversion : show line 1 in the form 10b5-1 | +200,000 | $3.85 | $770,000 | 1,854,597 | D |
| 2026-02-13 | Sale : show line 2 in the form 10b5-1 | −200,000 | $26.49 | $5,298,000 | 1,654,597 | D |
| Open-market sales · 200,000 sh · avg $26.49 · $5,298,000 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-13 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −200,000 | 5,044,834 | D |
Loading xslF345X05/wk-form4_1771455431.xml…